Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PER2 | O15055 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18964880 | 1.00 | DNM1 (0.51) | DNM1BACE1MAPTLMNAPTGDR2 | |
| SCHEMBL18965317 | 1.00 | DNM1 (0.51) | DNM1BACE1MAPTLMNAPTGDR2 | |
| SCHEMBL25661837 | 0.89 | MAPT (0.50) | DNM1MAPTLMNAPTGDR2KDM4E | |
| SCHEMBL18456794 | 0.76 | KDM4E (0.56) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL23774829 | 0.76 | MEN1 (0.60) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL21466931 | 0.76 | MEN1 (0.60) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7927457 | 0.76 | MEN1 (0.60) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL21008396 | 0.74 | APAF1 (0.56) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL21008394 | 0.74 | APAF1 (0.56) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL21008395 | 0.74 | APAF1 (0.56) | MAPTLMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10441570-B2 | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10035763-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | GTX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170166526-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | AR, BRCA1, FSHR | DNM1 4735/4885BACE1 835/4885MAPT 269/4885 |
| US-10441570-B2 | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof | AR, AHR, BRDT | DNM1 4266/4885BACE1 515/4885MAPT 407/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | DNM1 4266/4885BACE1 515/4885MAPT 407/4885 |
| US-20170166526-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, ADRM1 | DNM1 4422/4885BACE1 796/4885MAPT 574/4885 |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | DNM1 4266/4885BACE1 515/4885MAPT 407/4885 |
| US-10035763-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, ADRM1 | DNM1 4422/4885BACE1 796/4885MAPT 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.